Therapeutic Area
Oncology
ASCO 2026 Impact Survey: Reshaping Treatment Decisions for Oncology Future Standards of Care
What will have the greatest impact on cancer care following ASCO 2026? According to a survey from Syneos Health of 97 practicing oncologists who attended the meeting in person, the answer extends beyond any single study. Physicians point to a convergence of next-generation targeted therapies, precision oncology, artificial intelligence and biomarker-driven care that could reshape treatment decisions and future standards of care across oncology.
The ASCO 2026 Impact Survey examines the data, treatment modalities and emerging innovations generating the most excitement among oncologists.
Key findings include:
- Strong enthusiasm for next-generation small molecules targeting historically difficult pathways, particularly KRAS and RAS-driven cancers
- Continued momentum for antibody-drug conjugates (ADCs) as a leading modality in oncology innovation
- Practice-changing data in gastrointestinal, lung and breast cancers, with oncologists anticipating meaningful shifts in treatment approaches over the next three to five years
- Growing interest in advanced cell therapies, including dual-targeting and allogeneic CAR-T approaches
- Rising confidence in AI-enabled precision oncology, including multimodal AI models, biomarker-driven treatment selection and digital pathology applications
- Insights into the molecular targets, clinical readouts and oncology companies expected to have the greatest impact on future standards of care
Download the report to explore how oncologists are interpreting ASCO 2026 findings, which innovations are poised to influence clinical practice and what these trends could mean for oncology drug development, commercialization and patient care.
Related Content
Looking for exclusive insight?
